FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV524615617US

Express Mail Label Number

Date of Deposit

Form PTO-1390-MOD U. S. (REV 10-96)	Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER						
TRANSMITTAL LETTER TO 1	THE IMPLED STATES	LR/G-32918A U.S. APPLICATION NO. (If known, see 37 CFR 1.5)						
		10/536,543						
DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371								
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED						
PCT/SI2003/000043	25 November 2003 (25.11.03)	26 November 2002 (26.11.02)						
TITLE OF INVENTION PHARMACEUTICAL COMPOSITIONS COM	IPPISING AMOVICII I IN AND CLAV	/LILANIC ACID						
APPLICANT(S) FOR DO/EO/US	II NOING AMOXICILLIN AND CLAV	OLAINIC ACID						
KERC ET AL.								
Applicant herewith submits to the United States D	esignated/Elected Office (DO/EO/US) th	ne following items and other information:						
 This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 								
3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).								
 A proper Demand for International Prelim date. 								
 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. is transmitted herewith (required only if not transmitted by the International Bureau). b. has been transmitted by the International Bureau. (See Form PCT/IB/308) 								
c. is not required, as the application was filed in the United States Receiving Office (RO/US). A translation of the International Application into English (35 U.S.C. 371(c)(2)).								
7.	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)).							
b. have been transmitted by the Inte	d only if not transmitted by the Internation ernational Bureau.	•						
c. have not been made; however, to d. have not been made and will not		its has NOT expired.						
8. A translation of the amendments to the c	laims under PCT Article 19 (35 U.S.C. 3							
 An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 								
Items 11. to 16. below concern document(s) or	information included.							
11. An Information Disclosure Statement und	1. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.							
12. An assignment document for recording.	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.							
13. A FIRST preliminary amendment. A SECOND or SUBSEQUENT prelimina	ry amendment.							
14. An Application Data Sheet under 37 CFF	R 1.76.							
15. A substitute specification.								
16. A change of power of attorney and/or ad	dress letter.							
17. A computer-readable form of the sequen	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.							
18. A second copy of the published Internation	☐ A second copy of the published International Application under 35 U.S.C. 154(d)(4).							
19. A second copy of the English language to	ranslation of the International application	n under 35 U.S.C. 154(d)(4).						
20. Other items or information:								

U.S. APPLICATION NO. (if known, s 10/536,543	ee 37 CFR 1.5)	INTERNATIONAL APPLICATION NO. PCT/SI2003/000043	•	LR/G-329	OCKET NUMBER			
The following fees are submitted:			CALCULATIONS PTO USE ONLY					
24 Pagis nations	al foo	•		œ				
21. Basic national fee								
Examination Fee If International preliminary examination report was prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4) \$								
All other situations								
23. Search fee If Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority \$ If International Search Report was prepared and provided to the Office \$ All other situations								
TOTAL OF 21, 22 AND 23 =				\$ 0				
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.								
Total Sheets Extra		er of each additional 50 or fract f (round up to a whole number		RATE				
- 100 =	/50 =	•	X	\$ 250	\$			
Surcharge of \$130 for furnishing the oath of declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 130				
CLAIMS Total claims	NUMBER FILE	D NUMBER EXTRA 20 =	X	* 50	\$			
Independent claims		- 3 =	X	\$ 200	\$			
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 360				\$				
TOTAL OF ABOVE CALCULATIONS = Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be					\$ 130	•		
filed (Note 37 CFR 1.9, 1.27, 1.28).				\$				
SUBTOTAL = Processing fee of \$130 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)). +					\$ 130 \$			
TOTAL NATIONAL FEE =				\$ 130				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +				\$				
01/2005 MKAYPAGH 00000119 190134 10536543 TOTAL FEES ENCLOSED =					\$ 130			
FC:1617 130.00 DA		<i>3</i> .			Amount to be: refunded charged	\$		
a. A check in the amount of \$ to cover the above fees is enclosed.								
b. Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$130 to cover the above fees. A duplicate copy of this form is enclosed.								
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.								
		inder 37 CFR 1.494 or 1.495 l re the application to pending		en met, a petitior	n to revive (37 C	FR 1.137(a)		
Send all correspondence Customer No. 001095, w			John	That	Lemes			
Novartis Corporate Intelle One Health Plaza East Hanover, N	a, Building 104	Att Re	hn/Ø. Thall ofney for A g. No. 34,9 32) 778-79	Applicants 940				